55579-68-5

Usage

Uses

Used in Chemical Synthesis:
5-(2-Chlorophenyl)cyclohexane-1,3-dione is used as an intermediate in the synthesis of various chemical compounds. Its unique structure allows for further reactions and modifications, making it a valuable component in the production of pharmaceuticals, agrochemicals, or other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-(2-Chlorophenyl)cyclohexane-1,3-dione is used as a building block for the development of new drugs. Its chemical properties enable it to be incorporated into drug molecules, potentially leading to the creation of novel therapeutic agents with improved efficacy and safety profiles.
Used in Agrochemical Industry:
5-(2-Chlorophenyl)cyclohexane-1,3-dione is used as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its chemical structure can be tailored to target specific pests or weeds, providing an effective solution for agricultural challenges.
Used in Research and Development:
In the field of research and development, 5-(2-Chlorophenyl)cyclohexane-1,3-dione is used as a model compound for studying chemical reactions and mechanisms. Its reactivity and structural features make it an interesting subject for academic and industrial research, potentially leading to new discoveries and innovations.

InChI:InChI=1/C12H11ClO2/c13-12-4-2-1-3-11(12)8-5-9(14)7-10(15)6-8/h1-4,8H,5-7H2

Upstream product

• 91574-67-3 2-chlorobenzalacetone 
• 105-53-3 diethyl malonate 
• 24393-51-9 ethyl 3-(2-chlorophenyl)acrylate 
• 67-64-1 acetone 
• 89-98-5 2-chloro-benzaldehyde 

Downstream Products

• 80092-95-1 7-Chloro-3-(2-chloro-phenyl)-3,4-dihydro-2H,10H-acridine-1,9-dione 
• 55579-47-0 7-chloro-3-(2-chlorophenyl)-10-hydroxy-1-oxo-1,2,3,4-tetrahydro-9 (10H)-acridone 
• 51028-88-7 (2'-Chloro-5-methoxy-biphenyl-3-yl)-acetic acid 
• 239131-11-4 1-amino-5-(2-chlorophenyl)cyclohexen-3-one 
• 239130-87-1 (+/-)-7-(2-chlorophenyl)-4-methyl-5,6,7,8-tetrahydroquinolin-5-one 
• 1026238-82-3 5-(2-chlorophenyl)-1-[2-(4-methylphenylsulfonyl)hydrazino]cyclohexen-3-one 
• 239131-84-1 5-(2-chlorophenyl)-2-(1-hydroxy-2-methoxyethylidene)cyclohexane-1,3-dione 
• 239130-48-4 2-(1-hydroxyethylidene)-5-(2-chlorophenyl)cyclohexane-1,3-dione 
• 239130-53-1 5-(2-chlorophenyl)-2-propionylcyclohexane-1,3-dione 
• 239130-66-6 6-(2-chlorophenyl)-3-methyl-4,5,6,7-tetrahydrobenzofuran-4-one 
• 1372611-00-1 3-(2-chlorophenyl)-1-hydroxy-6H-benzo[c]chromen-6-one 
• 144128-60-9 7-Chloro-3-(2-chloro-phenyl)-1-[(E)-3-dimethylamino-propylimino]-10-hydroxy-1,3,4,10-tetrahydro-2H-acridin-9-one 
• 80092-68-8 7-Chloro-3-(2-chloro-phenyl)-1-[(E)-3-dimethylamino-propylimino]-1,3,4,10-tetrahydro-2H-acridin-9-one 

Relevant academic research and scientific papers

FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS

The present invention provides fused thiophene and thiazole derivatives of formula (I), which may be therapeutically useful, more particularly as RORγ modulators; in which R1, R2, R3, R4, R5, R6, R7, X1, X2, L, m, n and ring A have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in disease(s) or disorder(s) where there is an advantage in modulating RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the fused thiophene and thiazole derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons. Currently, there is only one FDA-approved treatment for ALS (riluzole), and that drug only extends life, on average, by 2-3 months. Mutations in Cu/Zn superoxide dismutase (SOD1) are found in familial forms of the disease and have played an important role in the study of ALS pathophysiology. On the basis of their activity in a PC12-G93A-YFP high-throughput screening assay, several bioactive compounds have been identified and classified as cyclohexane-1,3-dione (CHD) derivatives. A concise and efficient synthetic route has been developed to provide diverse CHD analogs. The structural modification of the CHD scaffold led to the discovery of a more potent analog (26) with an EC50 of 700 nM having good pharmacokinetic properties, such as high solubility, low human and mouse metabolic potential, and relatively good plasma stability. It was also found to efficiently penetrate the blood-brain barrier. However, compound 26 did not exhibit any significant life span extension in the ALS mouse model. It was found that, although 26 was active in PC12 cells, it had poor activity in other cell types, including primary cortical neurons, indicating that it can penetrate into the brain, but is not active in neuronal cells, potentially due to poor selective cell penetration. Further structural modification of the CHD scaffold was aimed at improving global cell activity as well as maintaining potency. Two new analogs (71 and 73) were synthesized, which had significantly enhanced cortical neuronal cell permeability, as well as similar potency to that of 26 in the PC12-G93A assay. These CHD analogs are being investigated further as novel therapeutic candidates for ALS.

Tandem reactions leading to benzo[c]chromen-6-ones and 3-substituted isocoumarins

A simple and convenient protocol for the synthesis of benzo[c]chromen-6- ones and 3-substituted isocoumarins through a CuI-catalyzed tandem reaction of 2-bromobenzoates withcyclohexane-1,3-diones or acyclic 1,3-diones is developed. This strategy can also be extended to the one-pot synthesis of isoquinolin-1(2H)-one and 3,4-dihydrophenanthridine-1,6(2H,5H)-dione. A simple and convenient protocol for the synthesis of benzo[c]chromen-6-ones and 3-substituted isocoumarins through a CuI-catalyzed tandem reaction of 2-bromobenzoates with cyclohexane-1,3-dione or acyclic 1,3-dione has been developed. This strategy can also be extended to the one-pot synthesis of isoquionlin-1(2H)-one and 3,4-dihydrophenanthridine-1,6-(2H,5H)-dione. Copyright

Consecutive Michael-claisen process for cyclohexane-1,3-dione derivative (CDD) synthesis from unsubstituted and substituted acetone 1

A long-existing problem of cyclohexane-1,3-dione derivatives (CDD) synthesis from unreactive acetone through consecutive Michael-Claisen process was solved under this study. The practical applicability of this process was tested for a novel compound ethyl 3-(2,4-dioxocyclohexyl)propanoate for up to 20-gram scale. Furthermore, the scope of different acetone derivatives was investigated and resulted with similar consecutive Michael-Claisen process for CDD synthesis. The reaction exhibited remarkable regioselectivity in Michael addition followed by Claisen cyclization. In this process high substrate selectivity was observed for CDD synthesis following consecutive double-Michael-Claisen and Michael-Claisen cyclization. Georg Thieme Verlag Stuttgart · New York.

PERNASAL PREPARATIONS

A nasal preparation comprising a compound represented by the formula: wherein Ring A is an optionally substituted 5- or 6-membered aromatic heterocyclic ring, Ring B is an optionally substituted 5- or 6-membered aromatic homocyclic or heterocyclic ring, R

Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof

The present invention is to provide a compound of the formula: wherein the ring A is an optionally substituted 5- to 6-membered aromatic heterocyclic ring, the ring B an optionally substituted 5- to 6-membered aromatic homocyclic ring or an optionally sub

Synthesis and Antimalarial Properties of 1-Imino Derivatives of 7-Chloro-3-substituted-3,4-dihydro-1,9(2H,10H)-acridinediones and Related Structures

To improve upon the activity and properties of the 3-aryl-7-chloro-3,4-dihydro-1,9(2H,10H)-acridinediones, a variety of 1-imino derivatives (3) were prepared and shown to be highly active antimalarial agents in both rodents and primates.Among structural modifications prepared, including N10-alkyl and C2-substituted analogs, removal of the C9 oxygen, and introduction of an imino side chain at C9, the imines of the N10-H acridinediones were the most active compounds obtained.The imino derivative of7-chloro-3-(2,4-dichlorophenyl)-3,4-dihydro-1,9(2H,10H)-acridinedione (9aa) proved to be highly active in advanced studies in primates.